News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: IHH Building $1 Billion Of China Hospitals; Seeks Deals For More



6/19/2017 5:17:12 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Malaysia's IHH Healthcare is building four China hospitals, a $1 billion investment, and it is looking for more, possibly through M&A deals; Australia's CSL Limited will pay $352 million to acquire an 80% controlling stake in China blood products company Ruide; WuXi Biologics rose 37% in the first day of Hong Kong trading following its $511 million IPO; Athenex, a US-China cancer biopharma, completed a $66 million IPO on the NASDAQ exchange; BeauCare Clinics, a Beijing aesthetic surgery clinic chain, raised $29 million in a Series B funding; Evasc Neurovascular of Canada closed a $7.5 million Series A round, led by Shanghai's Yonghua Capital; Lee's Pharm of Hong Kong in-licensed Asia rights to respiratory disease treatments from US-based Windtree in a $40 million deal; Venus Medtech of Hangzhou acquired InterValve, a US maker of transcatheter aortic valve devices; Sihuan Pharma formed a JV to distribute aesthetic products from Austria's Croma-Pharma; ACEA Biosciences, a San Diego-Hangzhou company, completed a successful Phase I trial of a novel BTK inhibitor; and Hutchison China MediTech announced the CFDA accepted a NDA for its lead drug, the cancer treatment fruquintinib.

Read at ChinaBio Today


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES